Novel lipoprotein(a) catabolism pathway via apolipoprotein(a) recycling: Adding the plasminogen receptor PlgR KT to the list

Circulation Research

Volumn 120, Issue 7, 2017, Pages 1050-1052

  Yeang, Calvin ^a   Gordts, Philip L S M ^b   Tsimikas, Sotirios ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

aortic valve stenosis; Editorials; LDL receptor; lipoprotein(a); PCSK9; plasminogen

Indexed keywords

APOLIPOPROTEIN A; LIPOPROTEIN A; PLASMINOGEN RECEPTOR; RECEPTOR; UNCLASSIFIED DRUG; PLASMINOGEN;

PRIORITY JOURNAL; PROTEIN DEGRADATION; REVIEW; ENDOCYTOSIS;

APOLIPOPROTEINS A; APOPROTEIN(A); ENDOCYTOSIS; LIPOPROTEIN(A); PLASMINOGEN;

EID: 85016755026     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.117.310700     Document Type: Review

References (15)

1. Tsimikas S, A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. J Am Coll Cardiol 2017 69 692 711. doi: 10.1016/j.jacc.2016.11.042.
2. KT -mediated endocytosis of lipoprotein(a). Circ Res 2017 120 1091 1102. doi: 10.1161/CIRCRESAHA.116.310272.
3. Yeang C, Wilkinson MJ, Tsimikas S, Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis. Curr Opin Cardiol 2016 31 440 450. doi: 10.1097/HCO.0000000000000300.
4. Romagnuolo R, Scipione CA, Boffa MB, Marcovina SM, Seidah NG, Koschinsky ML, Lipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptor. J Biol Chem 2015 290 11649 11662. doi: 10.1074/jbc.M114.611988.
5. Villard EF, Thedrez A, Blankenstein J, Croyal M, Tran T-T-T, Poirier B, Le Bail J-C, Illiano S, Nobécourt E, Krempf M, Blom DJ, Marais AD, Janiak P, Muslin AJ, Guillot E, Lambert G, PCSK9 Modulates the secretion but not the cellular uptake of lipoprotein(a) ex vivo. JACC: Basic to Translational Science 2016 1 419
6. Hofmann SL, Eaton DL, Brown MS, McConathy WJ, Goldstein JL, Hammer RE, Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J Clin Invest 1990 85 1542 1547. doi: 10.1172/JCI114602.
7. Raal FJ, Giugliano RP, Sabatine MS, PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. J Lipid Res 2016 57 1086 1096. doi: 10.1194/jlr.P065334.
8. Reyes-Soffer G, Pavlyha M, Ngai C, Effects of PCSK9 inhibition with alirocumab on lipoprotein metabolism in healthy humans. Circulation 2017 135 352 362. doi: 10.1161/CIRCULATIONAHA.116.025253.
9. Cain WJ, Millar JS, Himebauch AS, Tietge UJ, Maugeais C, Usher D, Rader DJ, Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]. J Lipid Res 2005 46 2681 2691. doi: 10.1194/jlr.M500249-JLR200.
10. Stein EA, Honarpour N, Wasserman SM, Xu F, Scott R, Raal FJ, Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. Circulation 2013 128 2113 2120. doi: 10.1161/CIRCULATIONAHA.113.004678.
11. Raal FJ, Hovingh GK, Blom D, Santos RD, Harada-Shiba M, Bruckert E, Couture P, Soran H, Watts GF, Kurtz C, Honarpour N, Tang L, Kasichayanula S, Wasserman SM, Stein EA, Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. Lancet Diabetes Endocrinol 2017 pii: S2213-8587(17)30044-X. doi: 10.1016/S2213-8587(17)30044-X.
12. Moriarty PM, Varvel SA, Gordts PL, McConnell JP, Tsimikas S, Lipoprotein(a) mass levels increase significantly according to APOE genotype: an analysis of 431 239 patients. Arterioscler Thromb Vasc Biol 2017 37 580 588. doi: 10.1161/ATVBAHA.116.308704.
13. Byun YS, Yang X, Bao W, DeMicco D, Laskey R, Witztum JL, Tsimikas S, SPARCL Trial Investigators Oxidized phospholipids on apolipoprotein B-100 and recurrent ischemic events following stroke or transient ischemic attack. J Am Coll Cardiol 2017 69 147 158. doi: 10.1016/j.jacc.2016.10.057.
14. Leibundgut G, Arai K, Orsoni A, Yin H, Scipione C, Miller ER, Koschinsky ML, Chapman MJ, Witztum JL, Tsimikas S, Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction. J Am Coll Cardiol 2012 59 1426 1437. doi: 10.1016/j.jacc.2011.12.033.
15. Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S, Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. Lancet 2016 388 2239 2253. doi: 10.1016/S0140-6736(16)31009-1.